Distribution and quantitative estimates of variant Creutzfeldt Jakob Diseases prions in the tissues of clinical and asymptomatic patients

Jean-Yves Douet; Caroline Lacroux; Naima Aron; Severine Lugan; Mark Head; Cecile Tillier; Alvina Huor; Herve Cassard; Mark Arnold; Vincent Beringue; James Ironside; Olivier Andreoletti

doi:10.3201/eid2306.161734

Distribution and quantitative estimates of variant Creutzfeldt Jakob Diseases prions in the tissues of clinical and asymptomatic patients

Jean-Yves Douet, Caroline Lacroux, Naima Aron, Severine Lugan, Mark Head, Cecile Tillier, Alvina Huor, Herve Cassard, Mark Arnold, Vincent Beringue, James Ironside, Olivier Andreoletti

Research output: Contribution to journal › Article › peer-review

Abstract

In the United-Kingdom, ≈1 of 2,000 persons could be infected with variant Creutzfeldt-Jakob disease (vCJD). Therefore, risk of transmission of vCJD by medical procedures remains a major concern for public health authorities. In this study, we used in vitro amplification of prions by protein misfolding cyclic amplification (PMCA) to estimate distribution and level of the vCJD agent in 21 tissues from 4 patients who died of clinical vCJD and from 1 asymptomatic person with vCJD. PMCA identified major levels of vCJD prions in a range of tissues, including liver, salivary gland, kidney, lung, and bone marrow. Bioassays confirmed that the quantitative estimate of levels of vCJD prion accumulation provided by PMCA are indicative of vCJD infectivity levels in tissues. Findings provide critical data for the design of measures to minimize risk for iatrogenic transmission of vCJD

Original language	English
Article number	6
Journal	Emerging Infectious Diseases
Early online date	19 Apr 2017
DOIs	https://doi.org/10.3201/eid2306.161734
Publication status	Published - Jun 2017

Access to Document

10.3201/eid2306.161734

Distribution and quantitative estimates of variant Creutzfeldt Jakob Diseases prions in the tissues of clinical and asymptomatic patients
This is author's peer-reviewed manuscript as accepted for publication
Accepted author manuscript, 4.21 MB

https://wwwnc.cdc.gov/eid/article/23/6/16-1734_article

Cite this

Douet, J.-Y., Lacroux, C., Aron, N., Lugan, S., Head, M., Tillier, C., Huor, A., Cassard, H., Arnold, M., Beringue, V., Ironside, J., & Andreoletti, O. (2017). Distribution and quantitative estimates of variant Creutzfeldt Jakob Diseases prions in the tissues of clinical and asymptomatic patients. Emerging Infectious Diseases, Article 6. https://doi.org/10.3201/eid2306.161734

@article{3f83e0e4fe8c46f8a43002581e2cd0ea,

title = "Distribution and quantitative estimates of variant Creutzfeldt Jakob Diseases prions in the tissues of clinical and asymptomatic patients",

abstract = "In the United-Kingdom, ≈1 of 2,000 persons could be infected with variant Creutzfeldt-Jakob disease (vCJD). Therefore, risk of transmission of vCJD by medical procedures remains a major concern for public health authorities. In this study, we used in vitro amplification of prions by protein misfolding cyclic amplification (PMCA) to estimate distribution and level of the vCJD agent in 21 tissues from 4 patients who died of clinical vCJD and from 1 asymptomatic person with vCJD. PMCA identified major levels of vCJD prions in a range of tissues, including liver, salivary gland, kidney, lung, and bone marrow. Bioassays confirmed that the quantitative estimate of levels of vCJD prion accumulation provided by PMCA are indicative of vCJD infectivity levels in tissues. Findings provide critical data for the design of measures to minimize risk for iatrogenic transmission of vCJD",

author = "Jean-Yves Douet and Caroline Lacroux and Naima Aron and Severine Lugan and Mark Head and Cecile Tillier and Alvina Huor and Herve Cassard and Mark Arnold and Vincent Beringue and James Ironside and Olivier Andreoletti",

year = "2017",

month = jun,

doi = "10.3201/eid2306.161734",

language = "English",

journal = "Emerging Infectious Diseases",

issn = "1080-6040",

publisher = "Centers for Disease Control and Prevention",

}

TY - JOUR

T1 - Distribution and quantitative estimates of variant Creutzfeldt Jakob Diseases prions in the tissues of clinical and asymptomatic patients

AU - Douet, Jean-Yves

AU - Lacroux, Caroline

AU - Aron, Naima

AU - Lugan, Severine

AU - Head, Mark

AU - Tillier, Cecile

AU - Huor, Alvina

AU - Cassard, Herve

AU - Arnold, Mark

AU - Beringue, Vincent

AU - Ironside, James

AU - Andreoletti, Olivier

PY - 2017/6

Y1 - 2017/6

N2 - In the United-Kingdom, ≈1 of 2,000 persons could be infected with variant Creutzfeldt-Jakob disease (vCJD). Therefore, risk of transmission of vCJD by medical procedures remains a major concern for public health authorities. In this study, we used in vitro amplification of prions by protein misfolding cyclic amplification (PMCA) to estimate distribution and level of the vCJD agent in 21 tissues from 4 patients who died of clinical vCJD and from 1 asymptomatic person with vCJD. PMCA identified major levels of vCJD prions in a range of tissues, including liver, salivary gland, kidney, lung, and bone marrow. Bioassays confirmed that the quantitative estimate of levels of vCJD prion accumulation provided by PMCA are indicative of vCJD infectivity levels in tissues. Findings provide critical data for the design of measures to minimize risk for iatrogenic transmission of vCJD

AB - In the United-Kingdom, ≈1 of 2,000 persons could be infected with variant Creutzfeldt-Jakob disease (vCJD). Therefore, risk of transmission of vCJD by medical procedures remains a major concern for public health authorities. In this study, we used in vitro amplification of prions by protein misfolding cyclic amplification (PMCA) to estimate distribution and level of the vCJD agent in 21 tissues from 4 patients who died of clinical vCJD and from 1 asymptomatic person with vCJD. PMCA identified major levels of vCJD prions in a range of tissues, including liver, salivary gland, kidney, lung, and bone marrow. Bioassays confirmed that the quantitative estimate of levels of vCJD prion accumulation provided by PMCA are indicative of vCJD infectivity levels in tissues. Findings provide critical data for the design of measures to minimize risk for iatrogenic transmission of vCJD

U2 - 10.3201/eid2306.161734

DO - 10.3201/eid2306.161734

M3 - Article

SN - 1080-6040

JO - Emerging Infectious Diseases

JF - Emerging Infectious Diseases

M1 - 6

ER -

Distribution and quantitative estimates of variant Creutzfeldt Jakob Diseases prions in the tissues of clinical and asymptomatic patients

Abstract

Access to Document

Fingerprint

Cite this